Abbott Beats Q2 Estimates, Lifts FY Outlook; Stock Surges 11%

What happened

Abbott Laboratories reported Q2 2026 adjusted EPS of $1.31, exceeding consensus of $1.28, and raised its full-year 2026 adjusted EPS guidance, sending shares up nearly 11%. The beat was driven by continued strong Medical Devices growth, particularly in Diabetes Care (CGM) and cardiology, which offset ongoing dilution from the Exact Sciences acquisition. The company's raised outlook implies confidence in sustaining Devices momentum and controlling integration costs, despite lingering headwinds from NEC infant-formula litigation and FDA remediation for Libre sensors. While the earnings report provides near-term validation, the full investment case hinges on Diagnostics acceleration from Exact and resolution of legal overhangs in the coming quarters.

Implication

Investors should use the post-earnings strength to reassess positions. While the beat is encouraging, the DeepValue master report's WAIT rating remains prudent: trim into strength above $105 and look to add on pullbacks toward $82, monitoring Q3 diagnostics disclosure and NEC trial outcomes. The raised guidance provides a floor, but the stock's next leg depends on proving that Exact integration lifts diagnostics growth and that FDA/Libre issues do not escalate.

Thesis delta

The Q2 beat and guidance raise shift the near-term risk/reward favorably, increasing confidence in the base case scenario ($95) and reducing probability of the bear case. However, the core investment thesis remains unchanged: Abbott must demonstrate that Exact Sciences integration accelerates Diagnostics growth without further EPS guide-downs, and that NEC litigation does not become a cash-flow overhang. The earnings report buys time but does not yet validate the bull case ($110).